Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
On MDCK cells and RAW264.7 cells, the highest non-toxic concentration (TC0) of cobalt protoporphyrin IX (72 h) is 3.13 μM [1]. In MDCK and RAW264.7 cells, cobalt protoporphyrin IX (2 μM; 0-24 h) raises the levels of intracellular protein HO-1 in a time-dependent way [1]. The antagonistic concentration (IC50) of Cobalt protoporphyrin IX against the influenza viruses Empty Cell A/Fort Monmouth /1/1947, A/TianjinJinnan /15/2009, A/Wuhan /359/1995, A/FujianTongan /196/2009, and BY/FujianXinluo /54/2006 are 0.40 ± 0.16, 0.42 ± 0.15, 0.46 ± 0.19, 0.34 ± 0.05, and 0.64 ± 0.30 μM, respectively [1]. Cobalt protoporphyrin IX (0.25-2 μM; 18 or 24 h) prevents IAV replication by boosting the IFN response; its anti-IAV action is not dependent on HO-1's catalytic role [1]. In order to boost antiviral IFN responses, IRF3 phosphorylation and translocation may be necessary for Cobalt protoporphyrin IX (2 μM; 0–6 h) to induce HO-1 anti-IAV activity [1].
|
---|---|
Cell Assay |
Western Blot Analysis[1]
Cell Types: MDCK cells and RAW264.7 cells Tested Concentrations: 2 μM Incubation Duration: 0, 3, 6, 12 and 24 h Experimental Results: Dramatically increased the intracellular protein levels of HO-1 in a time-dependent manner in MDCK cells and RAW264.7 cells. Real Time qPCR[1] Cell Types: RAW264.7 cells were infected with IAV A/Fort Monmouth/1/1947 (0.2 MOI) Tested Concentrations: 0.25, 0.5, 1 and 2 μM Incubation Duration: 18 h Experimental Results: Enhanced mRNA expressions of IFN-α/β, as well as protein expressions of some ISGs, such as IFN-inducible transmembrane protein 3 (IFITM3), double-stranded RNA-dependent protein kinase (PKR) and 2′-5′-oligoadenylate synthetase 1 (OAS1), in a dose-dependent manner. Western Blot Analysis[1] Cell Types: RAW264.7 cells or RAW264.7 cells infected with IAV A/Fort Monmouth/1/1947 (0.2 MOI) Tested Concentrations: 2 μM Incubation Duration: 0, 2, 4 and 6 h Experimental Results: Increased protein levels of IRF3 and p- IRF3. Promoted the cytoplasmic protein levels of IRF3 and p-IRF3 in RAW264.7 cells followi |
References |
[1]. Ma LL, et al. heme oxygenase-1 agonist CoPP suppresses influenza virus replication through IRF3-mediated generation of IFN-α/β. Virology. 2019 Feb;528:80-88.
|
Molecular Formula |
C34H32CON4O4
|
---|---|
Molecular Weight |
619.58
|
CAS # |
14325-03-2
|
SMILES |
[Co+2].OC(CCC1=C(C)C2[N-]C1=CC1[N-]C(C=C3N=C(C=C4N=C(C=2)C(C)=C4C=C)C(C)=C3C=C)=C(C)C=1CCC(=O)O)=O
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.6140 mL | 8.0700 mL | 16.1400 mL | |
5 mM | 0.3228 mL | 1.6140 mL | 3.2280 mL | |
10 mM | 0.1614 mL | 0.8070 mL | 1.6140 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.